Roche Annual General Meeting 2017

RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). The 855 attending shareholders, representing 86.3% of the total of 160,000,000 shares, approved the Annual Report, the Financial Statements and the Consolidated Financial Statements for 2016.

Christoph Franz was confirmed as Chairman of the Board of Directors with 99.98% of the votes represented. Anita Hauser was elected as a new member of the Board of Directors with 99.92% of the votes represented.

"Our more than 94,000 employees are committed every day to helping people with serious, life-threatening diseases. This commitment has allowed Roche to continue to make significant progress in 2016. I am confident that we are very well positioned to continue to deliver innovative medicines and diagnostics and make them accessible to patients worldwide," said Christoph Franz, Chairman of the Board of Directors. "I am delighted that Anita Hauser has been elected as a new member of the Board of Directors. She is a dynamic leader who brings extensive experience to the Board. After ten years on the Roche Board, Professor Pius Baschera had decided to not stand for re-election. On behalf of the Board of Directors, I would like to thank him most sincerely for his valuable contributions to Roche's success."

Shareholders also authorised the ratification of the Board of Directors' actions and approved an increase in the gross dividend for the past financial year to 8.20 Swiss francs (gross) per share and non-voting equity security. This is the 30th consecutive dividend increase.

Shareholders endorsed the total amount of bonuses paid to the Corporate Executive Committee for 2016 with 99.79% of the votes represented, as well as the bonus paid to the Chairman of the Board of Directors for 2016, which was approved by 99.61% of the votes represented. They also approved the maximum total amount of future remuneration of the Board of Directors, which was confirmed by 99.73% of the votes represented, and the maximum total amount of future remuneration for the Corporate Executive Committee until the 2018 ordinary Annual General Meeting by 99.72% of the votes represented.

In addition to Christoph Franz, all other Board members who stood for re-election were confirmed for a term of one year:

  • André Hoffmann
  • Professor Sir John Bell
  • Julie Brown
  • Paul Bulcke
  • Professor Richard P. Lifton
  • Dr Andreas Oeri
  • Bernard Poussot
  • Dr Severin Schwan
  • Dr Claudia Süssmuth Dyckerhoff
  • Peter R. Voser

The following Board members were elected to the Remuneration Committee:

  • Dr Christoph Franz
  • André Hoffmann
  • Professor Richard P. Lifton
  • Bernard Poussot
  • Peter R. Voser

KPMG AG was elected as external auditor for the financial year 2017 and BDO AG was elected as independent voting proxy until the conclusion of the next regular AGM in 2018.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Most Popular Now

FDA approves Roche's OCREVUS™ (ocrelizumab) for re…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both ...

Read more

First collaborative definition of patient centrici…

AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-d...

Read more

High doses of vitamin C to improve cancer treatmen…

Clinical trials found that it is safe to regularly infuse brain and lung cancer patients with 800 - 1000 times the daily recommended amount of vitamin C as a potential st...

Read more

Deep learning algorithm could boost drug developme…

Artificially intelligent algorithms can learn to identify amazingly subtle information, enabling them to distinguish between people in photos or to screen medical images ...

Read more

Bristol-Myers Squibb enters into separate agreemen…

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for ...

Read more

Tagrisso (osimertinib) receives US FDA full approv…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment...

Read more

A one-two punch hits pancreatic cancer where it hu…

Australian scientists have uncovered a promising new approach to treating pancreatic cancer, by targeting the tissue around the tumour to make it 'softer' and more respon...

Read more

FDA allows marketing of first direct-to-consumer t…

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are ...

Read more

Novartis to strengthen R&D pipeline by in-lice…

Novartis has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing condi...

Read more

New drug delivery system shows promise for fightin…

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiatio...

Read more

Towards a safe and scalable cell therapy for type …

More than 36 million people globally are affected by type 1 diabetes (T1D), a lifelong disorder where insulin producing cells are attacked and destroyed by the immune sys...

Read more

XELJANZ® (tofacitinib citrate) receives marketing …

Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination wi...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]